Laminin receptor mediates anti-inflammatory and anti-thrombogenic effects of pigment epithelium-derived factor in myeloma cells

Biochem Biophys Res Commun. 2014 Jan 17;443(3):847-51. doi: 10.1016/j.bbrc.2013.12.060. Epub 2013 Dec 14.

Abstract

Pigment epithelium-derived factor (PEDF) has anti-inflammatory and anti-thrombogenic properties both in cell culture and animal models. Although adipose triglyceride lipase (ATGL) and laminin receptor (LR) are two putative receptors for PEDF, which receptor mainly mediates the beneficial effects of PEDF is largely unknown. In this study, we addressed the issue. siRNA raised against LR (siLR) and siATGL transfection dramatically decreased LR and ATGL levels in human cultured myeloma cells, respectively. Ten nM PEDF significantly reduced vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), intercellular cell adhesion molecule-1 (ICAM-1) and plasminogen activator inhibitor-1 (PAI-1) mRNA levels in siCon- or siATGL-transfected myeloma cells, whereas PEDF increased rather than decreased these gene expressions in siLR-transfected cells. Neutralizing antibody directed against LR (LR-Ab) or LR antagonist actually bound to LR and reduced mRNA levels of VEGF, MCP-1, ICAM-1 and PAI-1 in myeloma cells. Further, pre-treatment of LR-Ab or LR antagonist suppressed the binding of PEDF to LR and resultantly blocked the effects of PEDF in myeloma cells. In addition, high concentration of LR agonist mimicked the actions of PEDF on these gene expressions in myeloma cells. This study indicates that PEDF causes anti-angiogenic, anti-inflammatory and anti-thrombogenic reactions in myeloma cells through the interaction with LR. Target domain of LR agonist and antagonist might be involved in the PEDF-signaling to gene suppression in myeloma cells.

Keywords: Inflammation; Laminin receptor; Myeloma cells; PEDF; Thrombogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / metabolism*
  • Cell Line, Tumor
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Eye Proteins / metabolism*
  • Eye Proteins / pharmacology
  • Fibrinolytic Agents / metabolism*
  • Gene Expression Regulation / drug effects
  • Humans
  • Intercellular Adhesion Molecule-1 / genetics
  • Intercellular Adhesion Molecule-1 / metabolism
  • Lipase / metabolism
  • Mice
  • Multiple Myeloma / metabolism*
  • Multiple Myeloma / pathology
  • Nerve Growth Factors / metabolism*
  • Nerve Growth Factors / pharmacology
  • Plasminogen Activator Inhibitor 1 / genetics
  • Plasminogen Activator Inhibitor 1 / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • RNA, Small Interfering / metabolism
  • Receptors, Laminin / antagonists & inhibitors
  • Receptors, Laminin / metabolism*
  • Serpins / metabolism*
  • Serpins / pharmacology
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Anti-Inflammatory Agents
  • CCL2 protein, human
  • Chemokine CCL2
  • Eye Proteins
  • Fibrinolytic Agents
  • Nerve Growth Factors
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • RNA, Small Interfering
  • Receptors, Laminin
  • Serpins
  • Vascular Endothelial Growth Factor A
  • pigment epithelium-derived factor
  • Intercellular Adhesion Molecule-1
  • Lipase
  • PNPLA2 protein, human